Elle, MD Secures C$1.1M to Advance Non-Hormonal Copper Vaginal Ring Clinical Trials

Summary

Vancouver-based Elle, MD Biotechnologies has raised C$1.1 million in pre-seed funding to transition its non-hormonal contraceptive ring, Livv, into human clinical studies. This capital supports a growing demand for effective birth control alternatives that bypass systemic hormonal side effects.

The company sits inside the Maternal & Newborn and Sexual & Reproductive lane of the women's health map at Pre-seed ($1.1M). Track it against comparable rounds to see whether pricing in this lane is holding.

Sources

• OVUM Primary source